ESMO-Magnitude of Clinical Benefit Scale

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

ESMO-MCBS insights

Teresa Amaral interviews Professor Martine Piccart who shares valuable insight on the ESMO-Magnitude of Clinical Benefit Scale (ESMO–MCBS)

 

ESMO-MCBS Visualisation prototype

Development is underway to create a visualisation of all ESMO-MCBS scores to find out more take a tour of the prototype and provide feedback by completing a short survey, please select below:

ESMO-MCBS Visualisation

ESMO-MCBS 

The scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from anti-cancer treatments.

The ESMO-MCBS is an important first step to the critical public policy issue of value in cancer care, helping to frame the appropriate use of limited public and personal resources to deliver cost-effective and affordable cancer care.

The ESMO-MCBS is a dynamic tool and its criteria revised on a regular basis.

For further information about ESMO-MCBS, please send an email to  mcbs@esmo.org

Introducing the ESMO Magnitude of Clinical Benefit Scale

Fortunato Ciardiello, Elisabeth de Vries, Josep Tabernero and Alexandru Eniu introduce The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) – a standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies.